Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Objective. To estimate the cost effectiveness of conventional versus intensive blood glucose control in patients with type 2 diabetes. Design. Incremental cost effectiveness analysis alongside randomised controlled trial. Setting. 23 UK hospital clinic based study centres. Participants. 3867 patients with newly diagnosed type 2 diabetes (mean age 53 years). Interventions. Conventional (primarily diet) glucose control policy versus intensive control policy with a sulphonylurea or insulin. Main outcome measures. Incremental cost per event-free year gained within the trial period. Results. Intensive glucose control increased trial treatment costs by u695 (95% confidence interval u555 to u836) per patient but reduced the cost of complications by u957 (u233 to u1681) compared with conventional management. If standard practice visit patterns were assumed rather than trial conditions, the incremental cost of intensive management was u478 (-u275 to u1232) per patient. The within trial event-free time gained in the intensive group was 0.60 (0.12 to 1.10) years and the lifetime gain 1.14 (0.69 to 1.61) years. The incremental cost per event-free year gained was u1166 (costs and effects discounted at 6% a year) and u563 (costs discounted at 6% a year and effects not discounted). Conclusions. Intensive blood glucose control in patients with type 2 diabetes significantly increased treatment costs but substantailly reduced the cost of complications and increased the time free of complications.

Type

Journal article

Journal

British Medical Journal

Publication Date

20/05/2000

Volume

320

Pages

1373 - 1378